Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 92-99

  Tiseo, Marcello ^a   Giovannetti, Elisa ^b   Tibaldi, Carmelo ^c   Camerini, Andrea ^d   Di Costanzo, Francesco ^e   Barbieri, Fausto ^f   Burgers, Jacobus A ^g   Vincent, Andrew ^g   Peters, Godefridus J ^b   Smit, Egbert F ^b   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Division of Oncology   (Italy)

^d Versilia Hospital   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Carboplatin; MTHFR C667T polymorphism; Non small cell lung cancer (NSCLC); Pemetrexed; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CARBOPLATIN; GAMMA GLUTAMYL HYDROLASE; PEMETREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; GGH GENE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MTHFR GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RFC GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY; TREATMENT OUTCOME; TSER GENE; XPD GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE FREQUENCY; GENOTYPE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; REDUCED FOLATE CARRIER PROTEIN; RETROSPECTIVE STUDIES; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 84866173015     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.009     Document Type: Article

References (32)

1. Azzoli C.G., Baker S., Temin S., Pao W., Aliff T., Brahmer J., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
2. D'Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E., et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Smit E.F., Burgers S.A., Biesma B., Smit H.J., Eppinga P., Dingemans A.M., et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:2038-2045.
5. Tiseo M., Ardizzoni A., Boni L., Vincent A., Buti S., Camerini A., et al. Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer: a pooled analysis of two randomized trials. J Thorac Oncol 2011, 6(Suppl. 2):S415. [abstract O32.02].
6. Chattopadhyay S., Moran R.G., Goldman I.D. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007, 6:404-417.
7. Adjei A.A., Mandrekar S.J., Dy G.K., Molina J.R., Adjei A.A., Gandara D.R., et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010, 28:614-619.
8. Adjei A.A., Salavaggione O.E., Mandrekar S.J., Dy G.K., Ziegler K.L., Endo C., et al. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 2010, 5:1346-1353.
9. Laverdière C., Chiasson S., Costea I., Moghrabi A., Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002, 100:3832-3834.
10. Cheng Q., Wu B., Kager L., Panetta J.C., Zheng J., Pui C.H., et al. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells. Pharmacogenetics 2004, 14:557-567.
11. Galvani E., Peters G.J., Giovannetti E. Thymidylate synthase inhibitors for non-small cell lung cancer. Expert Opin Investig Drugs 2011, 20:1343-1356.
12. Horie N., Aiba H., Oguro K., Hojo H., Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995, 20:191-197.
13. Marsh S., McKay J.A., Cassidy J., McLeod H.L. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 2001, 19:383-386.
14. Villafranca E., Okruzhnov Y., Dominguez M.A., García-Foncillas J., Azinovic I., Martínez E., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 2001, 19:1779-1786.
15. Jakobsen A., Nielsen J.N., Gyldenkerne N., Lindeberg J. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 2005, 23:1365-1369.
16. Kawakami K., Graziano F., Watanabe G., Ruzzo A., Santini D., Catalano V., et al. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin Cancer Res 2005, 11:3778-3783.
17. Schwab M., Zanger U.M., Marx C., Schaeffeler E., Klein K., Dippon J., et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008, 26:2131-2138.
18. Mauritz R., Giovannetti E., Beumer I.J., Smid K., Van Groeningen C.J., Pinedo H.M., et al. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer. Clin Colorectal Cancer 2009, 8:146-154.
19. Rosell R., Taron M., Camps C., López-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 2003, 39:775-786.
20. Wei S.Z., Zhan P., Shi M.Q., Shi Y., Qian Q., Yu L.K., et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol 2011, 28:315-321.
21. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
22. Giovannetti E., Zucali P.A., Peters G.J., Cortesi F., D'Incecco A., Smit E.F., et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010, 9:581-593.
23. Ciuleanu T., Brodowicz T., Zielinski C., Kim J.H., Krzakowski M., Laack E., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
24. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113.
25. Metro G., Chiari R., Mare M., Giannarelli D., Tofanetti F.R., Minotti V., et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 2011, 68:1405-1412.
26. Smit E.F., Socinski M.A., Mullaney B.P., Myrand S.P., Scagliotti G.V., Lorigan P., et al. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Ann Oncol 2011, December 19 [Epub ahead of print].
27. Argiris A., Karamouzis M.V., Gooding W.E., Branstetter B.F., Zhong S., Raez L.E., et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011, 29:1140-1145.
28. Argiris A., Karamouzis M.V., Smith R., Kotsakis A., Gibson M.K., Lai S.Y., et al. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol 2011, 22:2482-2488.
29. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007, 25:4528-4535.
30. Tibaldi C., Giovannetti E., Vasile E., Mey V., Laan A.C., Nannizzi S., et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008, 1:1797-1803.
31. Buikhuisen W.A., Burgers J.A., Vincent A.D., Schellens J.H., Beijnen J.H., Smit E.F., et al. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?. J Clin Oncol 2010, 28:e482-e483.
32. Stingl Kirchheiner J.C., Brockmöller J. Why, when, and how should pharmacogenetics be applied in clinical studies? Current and future approaches to study designs. Clin Pharmacol Ther 2011, 89:198-209.